Interventional Tumor Ablation Market Report 2026

Interventional Tumor Ablation Market Overview

• Interventional Tumor Ablation market size has reached to $1.77 billion in 2025 • Expected to grow to $2.66 billion in 2030 at a compound annual growth rate (CAGR) of 8.5% • Growth Driver: Rising Incidence Of Cancer Fueling The Growth Of The Market Due To Lifestyle And Environmental Factors • Market Trend: AI-Powered Tools Improve Treatment Planning And Outcomes • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Interventional Tumor Ablation Market?

Interventional tumor ablation is a minimally invasive procedure that uses image-guided techniques to destroy cancerous or benign tumors without the need for open surgery. It employs thermal or non-thermal energy to target and eliminate tumor cells. Interventional tumor ablation is used to treat localized tumors with minimal damage to surrounding healthy tissue, often used when surgery is not possible or as an alternative to traditional treatments. The main product types of interventional tumor ablation are open surgery, minimally invasive surgery, and image-guided interventions. Open surgery refers to a medical procedure where an incision is made in the body to access and treat an affected area, often involving the use of scalpels and other instruments. Key technologies in this field comprise radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, laser ablation, and high-intensity focused ultrasound (HIFU). Device types used in these procedures include ablation systems, consumables, support devices, and imaging systems. Tumor ablation is commonly applied to liver, kidney, lung, and bone tumors. The end users of these technologies range from hospitals and specialized cancer treatment centers to ambulatory surgical centers and research institutes.

What Is The Interventional Tumor Ablation Market Growth Forecast?

The interventional tumor ablation market size is expected to see strong growth in the next few years. It will grow to $2.66 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to increasing integration of ai-assisted imaging guidance, rising adoption of personalized cancer treatment, expansion of ambulatory surgical centers, growing investments in oncology device innovation, increasing demand for cost-effective cancer therapies. Major trends in the forecast period include increasing adoption of minimally invasive tumor ablation procedures, rising use of image-guided ablation technologies, expansion of microwave and radiofrequency ablation systems, growing demand for outpatient cancer treatments, enhanced focus on precision oncology.

Global Interventional Tumor Ablation Market Segmentation

1) By Procedure Type: Minimally Invasive Surgery, Image-Guided Interventions 2) By Technology: Radiofrequency Ablation (RFA), Microwave Ablation (MWA), Cryoablation, Laser Ablation, High-Intensity Focused Ultrasound (HIFU) 3) By Device Type: Ablation Systems, Consumables, Support Devices, Imaging Systems 4) By Application Area: Liver Tumors, Kidney Tumors, Lung Tumors, Bone Tumors 5) By End User: Hospitals, Specialized Cancer Treatment Centers, Ambulatory Surgical Centers, Research Institutes Subsegments: 1) By Minimally Invasive Surgery: Percutaneous Tumor Ablation, Endoscopic Ablation 2) By Image-Guided Interventions: Computed Tomography-Guided Tumor Ablation, Magnetic Resonance Imaging-Guided Tumor Ablation, Ultrasound-Guided Tumor Ablation

What Is The Driver Of The Interventional Tumor Ablation Market?

The rising incidence of cancer is expected to propel the growth of the interventional tumor ablation market going forward. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body, which can invade nearby tissues and potentially spread to other parts of the body through the blood and lymph systems. The rising incidence of cancer is primarily due to lifestyle and environmental factors such as smoking, poor diet, obesity, and exposure to carcinogens. Interventional tumor ablation enhances cancer treatment by offering minimally invasive techniques, offering patients a less invasive alternative to surgery. It reduces treatment time and recovery periods by providing precise tumor destruction, improving patient outcomes and quality of life. For instance, in February 2024, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, in 2025, over 35 million new cancer cases are predicted, a 77% increase from the estimated 20 million cases in 2022. Therefore, the rising incidence of cancer is driving the growth of the interventional tumor ablation industry.

Key Players In The Global Interventional Tumor Ablation Market

Major companies operating in the interventional tumor ablation market are Johnson & Johnson, Medtronic plc, Siemens Healthineers AG, Stryker Corporation, Boston Scientific Corporation, Olympus Corporation, Terumo Corporation, EDAP TMS S.A., Elekta AB, AngioDynamics Inc., InSightec Ltd., Cascination AG, IceCure Medical Ltd., Theraclion SA, Mermaid Medical Group A/S, H.S. Hospital Service S.p.A., Varian Medical Systems Inc., Neuwave Medical, BTG plc, MedWaves Inc., Perseon Medical AB, Chongqing Haifu Medical Technology Co. Ltd., AngioDynamics Nanoknife Division, Galil Medical Inc.

Global Interventional Tumor Ablation Market Trends and Insights

Major companies operating in the interventional tumor ablation market are focusing on developing technologically advanced solutions, such as BioTrace software suites, to improve precision and enhance the effectiveness of tumor ablation procedures. BioTrace software suites are integrated tools designed for tracking, managing, and analyzing biological data, particularly in research and healthcare environments. For instance, in July 2024, TechsoMed Medical Technologies Ltd., an Israel-based medical device company, launched BioTraceIO Vision and BioTraceIO Precision, software suites designed for image-guided liver tumor ablation therapy. BioTraceIO Vision offers artificial intelligence (AI)-powered personalized treatment planning and assessment tools using standard medical imaging to enhance the accuracy and efficiency of liver tumor ablation procedures. BioTraceIO Precision provides real-time ultrasound-based visualization and predictive mapping of the ablation zone during and after the procedure, helping clinicians assess tissue damage and treatment outcomes with high correlation to 24-hour post-ablation computed tomography (CT) scans.

What Are Latest Mergers And Acquisitions In The Interventional Tumor Ablation Market?

In February 2024, Immunophotonics Inc., a US-based biotechnology company, partnered with AngioDynamics Inc. This partnership aims to combine Immunophotonics’ lead immunotherapy asset, IP-001, with AngioDynamics’ ablation devices to explore the power of ablation in combination with immunotherapy for treating solid tumor cancers. AngioDynamics Inc. is a US-based medical device company offering microwave and radiofrequency ablation systems technologies for minimally invasive cancer treatment.

Regional Outlook

North America was the largest region in the interventional tumor ablation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Interventional Tumor Ablation Market?

The interventional tumor ablation market consists of revenues earned by entities by providing services such as electroporation, tumor biopsy services, thermal ablation monitoring, and post-ablation follow-up services. The market value includes the value of related goods sold by the service provider or included within the service offering. The interventional tumor ablation market also includes sales of radiofrequency ablation (RFA) generators, microwave ablation (MWA) systems, cryoablation probes, laser fibers and electrode needles. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.